Durability of antiviral response in hbeag-positive chronic hepatitis b patients who maintained virologic response for one year after lamivudine discontinuation

Digestive Diseases and Sciences

Volumn 54, Issue 7, 2009, Pages 1572-1577

  Kim, Ji Hoon ^a   Lee, Sun Jae ^a   Joo, Moon Kyung ^a   Kim, Chung Ho ^a   Choi, Jong Hwan ^a   Jung, Young Kul ^a   Yim, Hyung Joon ^a   Yeon, Jong Eun ^a   Park, Jong Jae ^a   Kim, Jae Seon ^a   Bak, Young Tae ^a   Byun, Kwan Soo ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Chronic hepatitis B; Durability; Lamivudine; Relapse; Response

Indexed keywords

HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADULT; ARTICLE; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; FEMALE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RECURRENT INFECTION;

ADULT; ANTIVIRAL AGENTS; DNA, VIRAL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; IMMUNORADIOMETRIC ASSAY; LAMIVUDINE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS; RISK FACTORS; VIRAL LOAD; VIRUS REPLICATION;

EID: 67349181363     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-008-0508-3     Document Type: Article

References (19)

1. AS Lok BJ McMahon 2007 Chronic hepatitis B Hepatology 45 507 539 (Pubitemid 46374607)
2. YF Liaw N Leung R Guan GK Lau I Merican G McCaughan 2005 Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update Liver Int 25 472 489 (Pubitemid 40861895)
3. CN Chang V Skalski JH Zhou YC Cheng 1992 Biochemical pharmacology of (+)- and (-)-2, 3'-dideoxy-3'-thiacytidine as anti-hepatitis B virus agents J Biol Chem 267 22414 22420
4. JL Dienstag RP Perrillo ER Schiff M Bartholomew C Vicary M Rubin 1995 A preliminary trial of lamivudine for chronic hepatitis B infection N Engl J Med 333 1657 1661 (Pubitemid 26001954)
5. CL Lai RN Chien NW Leung TT Chang R Guan DI Tai 1998 A 1-year trial of lamivudine for chronic hepatitis B Asia Hepatitis Lamivudine Study Group N Engl J Med 339 61 68
6. K Chayama Y Suzuki M Kobayashi M Kobayashi A Tsubota M Hashimoto 1998 Emergence and takeover of YMDD motif mutant hepatitis B virus during long-term lamivudine therapy and re-takeover by wild type after cessation of therapy Hepatology 27 1711 1716 (Pubitemid 28264699)
7. P Honkoop HG Niesters RA de Man AD Osterhaus SW Schalm 1997 Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns J Hepatol 26 1393 1395 (Pubitemid 27346654)
8. YF Liaw NW Leung TT Chang R Guan DI Tai KY Ng 2000 Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group Gastroenterology 119 172 180
9. KS Byun OS Kwon JH Kim HJ Yim YJ Chang JY Kim 2005 Factors related to post-treatment relapse in chronic hepatitis B patients who lost HBeAg after lamivudine therapy J Gastroenterol Hepatol 20 1838 1842 (Pubitemid 43961038)
10. KM Lee SW Cho SW Kim HJ Kim KB Hahm JH Kim 2002 Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion J Viral Hepat 9 208 212 (Pubitemid 36005519)
11. BC Song DJ Suh HC Lee YH Chung YS Lee 2000 Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea Hepatology 32 803 806 (Pubitemid 30744279)
12. JL Dienstag J Cianciara S Karayalcin KV Kowdley B Willems S Plisek 2003 Durability of serologic response after lamivudine treatment of chronic hepatitis B Hepatology 37 748 755 (Pubitemid 36397384)
13. SK Yoon JW Jang CW Kim SH Bae JY Choi SW Choi 2005 Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: Response and relapse rates, and factors related to durability of HBeAg seroconversion Intervirology 48 341 349
14. SH Ryu YH Chung MH Choi JA Kim JW Shin MK Jang 2003 Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study J Hepatol 39 614 619 (Pubitemid 37204663)
15. RN Chien CT Yeh SL Tsai CM Chu YF Liaw 2003 Determinants for sustained HBeAg response to lamivudine therapy Hepatology 38 1267 1273
16. X Ding M Mizokami G Yao B Xu E Orito R Ueda 2001 Hepatitis B virus genotype distribution among chronic hepatitis B virus carriers in Shanghai, China Intervirology 44 43 47 (Pubitemid 32172943)
17. E Orito T Ichida H Sakugawa M Sata N Horiike K Hino 2001 Geographic distribution of hepatitis B virus (HBV) genotype in patients with chronic HBV infection in Japan Hepatology 34 590 594 (Pubitemid 32786652)
18. JH Kao 2002 Hepatitis B viral genotypes: Clinical relevance and molecular characteristics J Gastroenterol Hepatol 17 643 650
19. SD Pas RA de Man E Fries AD Osterhaus HG Niesters 2002 The dynamics of mutations in the YMDD motif of the hepatitis B virus polymerase gene during and after lamivudine treatment as determined by reverse hybridisation J Clin Virol 25 63 71 (Pubitemid 34765764)